SinoMab FY26 H1 loss widens to RMB 127.4 million; funding available drops to RMB 196.5 million

• SinoMab posted a net loss of RMB 127.4 million for the six months ended June 30, 2026, versus RMB 49.8 million a year earlier.
• Excluding a one-off non-current asset impairment of RMB 56.3 million, net loss widened 42.77% to RMB 71.1 million.
• Total funding available fell 44.1% to RMB 196.5 million as of June 30 from Dec. 31, 2025.
• Loss increase attributed to higher lab and experiment costs tied to starting SM17’s Phase 2 atopic dermatitis trial in China.
• SM17 Phase 2 in China enrolled 86 patients by June 30; enrolment completion targeted for Q3 2026, topline data expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309812), on August 31, 2026, and is solely responsible for the information contained therein.